Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine - Based Immunoprophylactic Regimens With MPA TDM.

Trial Profile

Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine - Based Immunoprophylactic Regimens With MPA TDM.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2011

At a glance

  • Drugs Ciclosporin; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Prednisone; Tacrolimus
  • Indications Heart transplant rejection
  • Focus Biomarker; Therapeutic Use
  • Sponsors Astellas Pharma; Astellas Pharma Canada
  • Most Recent Events

    • 24 Feb 2011 Last checked against ClinicalTrials.gov record.
    • 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jul 2008 The expected completion date for this trial has changed from May 2008 to Jul 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top